Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $15,913 | 6 | 70.7% |
| Unspecified | $4,470 | 3 | 19.9% |
| Travel and Lodging | $1,751 | 6 | 7.8% |
| Food and Beverage | $371.41 | 5 | 1.7% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $9,299 | 10 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $8,736 | 7 | $0 (2017) |
| PFIZER INC. | $4,470 | 3 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $3,200 | 1 | PFIZER INC. ($3,200) |
| 2021 | $3,588 | 1 | E.R. Squibb & Sons, L.L.C. ($3,588) |
| 2020 | $1,270 | 2 | PFIZER INC. ($1,270) |
| 2019 | $5,011 | 8 | E.R. Squibb & Sons, L.L.C. ($5,011) |
| 2018 | $700.00 | 1 | E.R. Squibb & Sons, L.L.C. ($700.00) |
| 2017 | $8,736 | 7 | Novartis Pharmaceuticals Corporation ($8,736) |
All Payment Transactions
20 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/03/2023 | PFIZER INC. | XELJANZ (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: TOFACITINIB CLINICAL PUBLICATION PROGRAM • Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 08/24/2021 | E.R. Squibb & Sons, L.L.C. | ORENCIA (Biological) | Consulting Fee | Cash or cash equivalent | $3,587.50 | General |
| Category: Immunology | ||||||
| 11/09/2020 | PFIZER INC. | XELJANZ (Drug) | — | In-kind items and services | $940.00 | Research |
| Study: TOFACITINIB CLINICAL PUBLICATION PROGRAM • Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 06/16/2020 | PFIZER INC. | XELJANZ (Drug) | — | In-kind items and services | $330.00 | Research |
| Study: TOFACITINIB CLINICAL PUBLICATION PROGRAM • Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 09/09/2019 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,185.92 | General |
| 06/20/2019 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $3,150.00 | General |
| 06/12/2019 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $97.16 | General |
| 04/15/2019 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $67.78 | General |
| 04/15/2019 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $57.32 | General |
| 04/15/2019 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $33.31 | General |
| 04/15/2019 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $31.81 | General |
| 04/14/2019 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $387.91 | General |
| 04/11/2018 | E.R. Squibb & Sons, L.L.C. | ORENCIA (Biological) | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| Category: Immunology | ||||||
| 12/09/2017 | Novartis Pharmaceuticals Corporation | ILARIS (Biological) | Consulting Fee | Cash or cash equivalent | $7,192.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/09/2017 | Novartis Pharmaceuticals Corporation | ILARIS (Biological) | Travel and Lodging | In-kind items and services | $357.98 | General |
| Category: IMMUNOLOGY | ||||||
| 12/09/2017 | Novartis Pharmaceuticals Corporation | ILARIS (Biological) | Travel and Lodging | Cash or cash equivalent | $296.17 | General |
| Category: IMMUNOLOGY | ||||||
| 12/09/2017 | Novartis Pharmaceuticals Corporation | ILARIS (Biological) | Food and Beverage | In-kind items and services | $118.98 | General |
| Category: IMMUNOLOGY | ||||||
| 12/09/2017 | Novartis Pharmaceuticals Corporation | ILARIS (Biological) | Food and Beverage | Cash or cash equivalent | $94.02 | General |
| Category: IMMUNOLOGY | ||||||
| 12/09/2017 | Novartis Pharmaceuticals Corporation | ILARIS (Biological) | Travel and Lodging | Cash or cash equivalent | $34.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/08/2017 | Novartis Pharmaceuticals Corporation | ILARIS (Biological) | Travel and Lodging | In-kind items and services | $643.00 | General |
| Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| TOFACITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $4,470 | 3 |
About Dr. Lawrence Jung, M.D
Dr. Lawrence Jung, M.D is a Pediatric Rheumatology healthcare provider based in Washington, District of Columbia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/30/2006. The National Provider Identifier (NPI) number assigned to this provider is 1902916182.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Lawrence Jung, M.D has received a total of $22,505 in payments from pharmaceutical and medical device companies, with $3,200 received in 2023. These payments were reported across 20 transactions from 3 companies. The most common payment nature is "Consulting Fee" ($15,913).
Practice Information
- Specialty Pediatric Rheumatology
- Other Specialties Pediatric Rheumatology, Pediatrics
- Location Washington, DC
- Active Since 08/30/2006
- Last Updated 01/12/2024
- Taxonomy Code 2080P0216X
- Entity Type Individual
- NPI Number 1902916182
Products in Payments
- ILARIS (Biological) $8,736
- XELJANZ (Drug) $4,470
- ORENCIA (Biological) $4,288
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatric Rheumatology Doctors in Washington
Sangeeta Sule, M.d, M.D
Pediatric Rheumatology — Payments: $12,528
Matthew Eremita, Md, MD
Pediatric Rheumatology — Payments: $474.58
Ellen Goldmuntz, Md, MD
Pediatric Rheumatology — Payments: $177.01
Abigail Bosk, Do, DO
Pediatric Rheumatology — Payments: $133.89
Ms. Jessica Simpson, M.d, M.D
Pediatric Rheumatology — Payments: $50.11
Jane Filie, Md, MD
Pediatric Rheumatology